메뉴 건너뛰기




Volumn 14, Issue 9, 2018, Pages 511-527

Major lung complications of systemic sclerosis

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; MACITENTAN; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL; IMMUNOSUPPRESSIVE AGENT;

EID: 85052244199     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/s41584-018-0062-0     Document Type: Review
Times cited : (76)

References (171)
  • 2
    • 85017417416 scopus 로고    scopus 로고
    • Early mortality in a multinational systemic sclerosis inception cohort
    • Hao, Y. et al. Early mortality in a multinational systemic sclerosis inception cohort. Athritis Rheumatol. 69, 1067–1077 (2017)
    • (2017) Athritis Rheumatol. , vol.69 , pp. 1067-1077
    • Hao, Y.1
  • 3
    • 85030983267 scopus 로고    scopus 로고
    • Mapping and predicting mortality from systemic sclerosis
    • PID: 28835464
    • Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 76, 1897–1905 (2017)
    • (2017) Ann. Rheum. Dis. , vol.76 , pp. 1897-1905
    • Elhai, M.1
  • 4
    • 85029959797 scopus 로고    scopus 로고
    • Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE)
    • PID: 28229826
    • Rubio-Rivas, M. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin. Exp. Rheumatol. 35 (Suppl. 106), 40–47 (2017)
    • (2017) Clin. Exp. Rheumatol. , vol.35 , pp. 40-47
    • Rubio-Rivas, M.1
  • 5
    • 85017469832 scopus 로고    scopus 로고
    • Systemic sclerosis
    • PID: 28413064
    • Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685–1699 (2017)
    • (2017) Lancet , vol.390 , pp. 1685-1699
    • Denton, C.P.1    Khanna, D.2
  • 6
    • 84953343033 scopus 로고    scopus 로고
    • Systemic sclerosis: from pathogenesis to targeted therapy
    • PID: 26457375
    • Denton, C. P. Systemic sclerosis: from pathogenesis to targeted therapy. Clin. Exp. Rheumatol. 33, S3–7 (2015)
    • (2015) Clin. Exp. Rheumatol. , vol.33 , pp. S3-S7
    • Denton, C.P.1
  • 7
    • 84896283016 scopus 로고    scopus 로고
    • Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease
    • PID: 24574206, (2014
    • Silver, R. M. & Feghali-Bostwick, C. A. Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 66, 485–487 (2014) (2014)
    • (2014) Arthritis Rheumatol. , vol.66 , pp. 485-487
    • Silver, R.M.1    Feghali-Bostwick, C.A.2
  • 8
    • 79953677802 scopus 로고    scopus 로고
    • Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension
    • PID: 21360508
    • Hsu, E. et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 63, 783–794 (2011)
    • (2011) Arthritis Rheum. , vol.63 , pp. 783-794
    • Hsu, E.1
  • 9
    • 84880855616 scopus 로고    scopus 로고
    • Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease
    • PID: 23915349
    • Lindahl, G. E. et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir. Res. 14, 80 (2013)
    • (2013) Respir. Res. , vol.14 , pp. 80
    • Lindahl, G.E.1
  • 10
    • 34447520311 scopus 로고    scopus 로고
    • Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression
    • PID: 17530640
    • Goh, N. S. et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 56, 2005–2012 (2007)
    • (2007) Arthritis Rheum. , vol.56 , pp. 2005-2012
    • Goh, N.S.1
  • 11
    • 0030883273 scopus 로고    scopus 로고
    • Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis
    • PID: 9214423
    • Shi-Wen, X. et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum. 40, 1237–1244 (1997)
    • (1997) Arthritis Rheum. , vol.40 , pp. 1237-1244
    • Shi-Wen, X.1
  • 12
    • 37149016368 scopus 로고    scopus 로고
    • Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts
    • PID: 18050250
    • Shi-wen, X. & Kennedy, L. et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum. 56, 4189–4194 (2007)
    • (2007) Arthritis Rheum. , vol.56 , pp. 4189-4194
    • Shi-wen, X.1    Kennedy, L.2
  • 13
    • 36549062970 scopus 로고    scopus 로고
    • Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts
    • PID: 17681742
    • Shi-Wen, X. et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. 26, 625–632 (2007)
    • (2007) Matrix Biol. , vol.26 , pp. 625-632
    • Shi-Wen, X.1
  • 14
    • 84922967715 scopus 로고    scopus 로고
    • Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
    • PID: 25502501
    • Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L344–357 (2015)
    • (2015) Am. J. Physiol. Lung Cell. Mol. Physiol. , vol.308 , pp. L344-L357
    • Liu, F.1
  • 15
    • 84952064198 scopus 로고    scopus 로고
    • Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease
    • PID: 26360820
    • Mendoza, F. A., Piera-Velazquez, S., Farber, J. L., Feghali-Bostwick, C. & Jiménez, S. A. Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 68, 210–217 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 210-217
    • Mendoza, F.A.1    Piera-Velazquez, S.2    Farber, J.L.3    Feghali-Bostwick, C.4    Jiménez, S.A.5
  • 16
    • 84879298794 scopus 로고    scopus 로고
    • Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells
    • PID: 23796020
    • Gilbane, A. J., Denton, C. P. & Holmes, A. M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res. Ther. 15, 215 (2013)
    • (2013) Arthritis Res. Ther. , vol.15 , pp. 215
    • Gilbane, A.J.1    Denton, C.P.2    Holmes, A.M.3
  • 17
    • 84875861264 scopus 로고    scopus 로고
    • Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis
    • PID: 23378460
    • De Lauretis, A. et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J. Rheumatol. 40, 435–446 (2013)
    • (2013) J. Rheumatol. , vol.40 , pp. 435-446
    • De Lauretis, A.1
  • 18
    • 84893081873 scopus 로고    scopus 로고
    • Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis
    • PID: 24350901
    • van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433–443 (2014)
    • (2014) N. Engl. J. Med. , vol.370 , pp. 433-443
    • van Bon, L.1
  • 19
    • 85028396582 scopus 로고    scopus 로고
    • CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts
    • PID: 28575534
    • Wu, M. et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol. 69, 1871–1878 (2017)
    • (2017) Arthritis Rheumatol. , vol.69 , pp. 1871-1878
    • Wu, M.1
  • 20
    • 0042090396 scopus 로고    scopus 로고
    • Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice
    • Denton, C. P. et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J. Biol. Chem. 278, 25109–25119 (2013)
    • (2013) J. Biol. Chem. , vol.278 , pp. 25109-25119
    • Denton, C.P.1
  • 21
    • 79960184890 scopus 로고    scopus 로고
    • Increased epithelial permeability in pulmonary fibrosis in relation to disease progression
    • PID: 21030449
    • Goh, N. S. et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur. Respir. J. 38, 184–190 (2011)
    • (2011) Eur. Respir. J. , vol.38 , pp. 184-190
    • Goh, N.S.1
  • 22
    • 84962246398 scopus 로고    scopus 로고
    • Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study
    • PID: 27033049
    • Richardson, C. et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin. Arthritis Rheum. 46, 109–114 (2016)
    • (2016) Semin. Arthritis Rheum. , vol.46 , pp. 109-114
    • Richardson, C.1
  • 23
    • 78649448568 scopus 로고    scopus 로고
    • Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence
    • PID: 20494406
    • Christmann, R. B., Wells, A. U., Capelozzi, V. L. & Silver, R. M. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin. Arthritis Rheum. 40, 241–249 (2010)
    • (2010) Semin. Arthritis Rheum. , vol.40 , pp. 241-249
    • Christmann, R.B.1    Wells, A.U.2    Capelozzi, V.L.3    Silver, R.M.4
  • 24
    • 84889886646 scopus 로고    scopus 로고
    • Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs
    • PID: 24216753
    • Henderson, N. C. et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617–1624 (2013)
    • (2013) Nat. Med. , vol.19 , pp. 1617-1624
    • Henderson, N.C.1
  • 25
    • 33846247466 scopus 로고    scopus 로고
    • Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma
    • PID: 17195237
    • Sonnylal, S. et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 56, 334–344 (2007)
    • (2007) Arthritis Rheum. , vol.56 , pp. 334-344
    • Sonnylal, S.1
  • 26
    • 42449125545 scopus 로고    scopus 로고
    • Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model
    • PID: 18383385
    • Hoyles, R. K. et al. Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 58, 1175–1188 (2008)
    • (2008) Arthritis Rheum. , vol.58 , pp. 1175-1188
    • Hoyles, R.K.1
  • 27
    • 78751694228 scopus 로고    scopus 로고
    • An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor
    • PID: 20709822
    • Hoyles, R. K. et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am. J. Respir. Crit. Care Med. 183, 249–261 (2011)
    • (2011) Am. J. Respir. Crit. Care Med. , vol.183 , pp. 249-261
    • Hoyles, R.K.1
  • 28
    • 85021363940 scopus 로고    scopus 로고
    • Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis
    • PID: 28651005
    • Watanabe, T. et al. Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis. PLOS One 12, e0179917 (2017)
    • (2017) PLOS One , vol.12
    • Watanabe, T.1
  • 29
    • 84962892510 scopus 로고    scopus 로고
    • Netrin-1 regulates fibrocyte accumulation in the decellularized fibrotic sclerodermatous lung microenvironment and in bleomycin-induced pulmonary fibrosis
    • PID: 26749424
    • Sun, H. et al. Netrin-1 regulates fibrocyte accumulation in the decellularized fibrotic sclerodermatous lung microenvironment and in bleomycin-induced pulmonary fibrosis. Arthritis Rheumatol. 68, 1251–1261 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 1251-1261
    • Sun, H.1
  • 30
    • 85033451265 scopus 로고    scopus 로고
    • Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
    • PID: 29121645
    • Tourkina, E. et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogen. Tissue Repair. 4, 15 (2011)
    • (2017) PLOS One , vol.12
    • Martyanov, V.1
  • 31
    • 80051600437 scopus 로고    scopus 로고
    • Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide
    • Misharin, A. V. et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J. Exp. Med. 214, 2387–2404 (2017)
    • (2011) Fibrogen. Tissue Repair. , vol.4 , pp. 15
    • Tourkina, E.1
  • 32
    • 85027381168 scopus 로고    scopus 로고
    • Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
    • PID: 28694385
    • Martyanov, V. et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLOS One 12, e0187580 (2017)
    • (2017) J. Exp. Med. , vol.214 , pp. 2387-2404
    • Misharin, A.V.1
  • 33
    • 84886790538 scopus 로고    scopus 로고
    • Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis
    • PID: 23897225
    • Assassi, S. et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 65, 2917–2927 (2013)
    • (2013) Arthritis Rheum. , vol.65 , pp. 2917-2927
    • Assassi, S.1
  • 34
    • 85016101947 scopus 로고    scopus 로고
    • A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
    • PID: 28330499
    • Taroni, J. N. et al. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 9, 27 (2017)
    • (2017) Genome Med. , vol.9
    • Taroni, J.N.1
  • 35
    • 84891817885 scopus 로고    scopus 로고
    • Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis
    • PID: 24387989
    • Mayes, M. D. et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47–61 (2014)
    • (2014) Am. J. Hum. Genet. , vol.94 , pp. 47-61
    • Mayes, M.D.1
  • 36
    • 84876281483 scopus 로고    scopus 로고
    • Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis
    • PID: 23321605
    • Stock, C. J. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68, 436–441 (2013)
    • (2013) Thorax , vol.68 , pp. 436-441
    • Stock, C.J.1
  • 37
    • 84859935899 scopus 로고    scopus 로고
    • A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis
    • PID: 22531499
    • Bossini-Castillo, L. et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res. Ther. 14, R85 (2012)
    • (2012) Arthritis Res. Ther. , vol.14 , pp. R85
    • Bossini-Castillo, L.1
  • 38
    • 14044263005 scopus 로고    scopus 로고
    • Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma
    • PID: 15546965
    • Lagan, A. L. et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology 44, 197–201 (2005)
    • (2005) Rheumatology , vol.44 , pp. 197-201
    • Lagan, A.L.1
  • 39
    • 85039861203 scopus 로고    scopus 로고
    • Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes
    • PID: 28800254
    • Chu, H. et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am. J. Respir. Cell. Mol. Biol. 58, 28–39 (2018)
    • (2018) Am. J. Respir. Cell. Mol. Biol. , vol.58 , pp. 28-39
    • Chu, H.1
  • 40
    • 34548843398 scopus 로고    scopus 로고
    • A polymorphism in the CTGF promoter region associated with systemic sclerosis
    • PID: 17881752
    • Fonseca, C. et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357, 1210–1220 (2007)
    • (2007) N. Engl. J. Med. , vol.357 , pp. 1210-1220
    • Fonseca, C.1
  • 41
    • 72249112140 scopus 로고    scopus 로고
    • Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population
    • Kawaguchi, Y. et al. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann. Rheum. Dis. 68, 1921–1924 (2001)
    • (2001) Ann. Rheum. Dis. , vol.68 , pp. 1921-1924
    • Kawaguchi, Y.1
  • 42
    • 84866182297 scopus 로고    scopus 로고
    • Association between the CTGF -945C/G polymorphism and systemic sclerosis: a meta-analysis
    • PID: 22906474
    • Rueda, B. et al. A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann. Rheum. Dis. 68, 1618–1620 (2009)
    • (2012) Gene , vol.509 , pp. 1-6
    • Zhang, X.1    Nie, S.2    Si, X.3    Luo, Y.4    Tang, W.5
  • 43
    • 70349386180 scopus 로고    scopus 로고
    • A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype
    • PID: 19054816
    • Zhang, X., Nie, S., Si, X., Luo, Y. & Tang, W. Association between the CTGF -945C/G polymorphism and systemic sclerosis: a meta-analysis. Gene 509, 1–6 (2012)
    • (2009) Ann. Rheum. Dis. , vol.68 , pp. 1618-1620
    • Rueda, B.1
  • 44
    • 85018831799 scopus 로고    scopus 로고
    • The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms
    • PID: 28434122
    • Zhao, W. et al. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. Rheumatol Int. 37, 1303–1310 (2017)
    • (2017) Rheumatol Int. , vol.37 , pp. 1303-1310
    • Zhao, W.1
  • 45
    • 85008669389 scopus 로고    scopus 로고
    • miR-155 in the progression of lung fibrosis in systemic sclerosis
    • PID: 27377409
    • Christmann, R. B. et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res. Ther. 18, 155 (2016)
    • (2016) Arthritis Res. Ther. , vol.18 , pp. 155
    • Christmann, R.B.1
  • 46
    • 84880588126 scopus 로고    scopus 로고
    • Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis
    • PID: 23759512
    • Tang, X. et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 183, 470–479 (2013)
    • (2013) Am. J. Pathol. , vol.183 , pp. 470-479
    • Tang, X.1
  • 47
    • 85032017630 scopus 로고    scopus 로고
    • Early-life antibiotic exposure causes intestinal dysbiosis and exacerbates skin and lung pathology in experimental systemic sclerosis
    • PID: 28757138
    • Mehta, H. et al. Early-life antibiotic exposure causes intestinal dysbiosis and exacerbates skin and lung pathology in experimental systemic sclerosis. J. Invest. Dermatol. 137, 2316–2325 (2017)
    • (2017) J. Invest. Dermatol. , vol.137 , pp. 2316-2325
    • Mehta, H.1
  • 48
    • 85031684555 scopus 로고    scopus 로고
    • Role of stromelysin 2 (matrix metalloproteinase 10) as a novel mediator of vascular remodeling underlying pulmonary hypertension associated with systemic sclerosis
    • PID: 28805015
    • Avouac, J. et al. Role of stromelysin 2 (matrix metalloproteinase 10) as a novel mediator of vascular remodeling underlying pulmonary hypertension associated with systemic sclerosis. Arthritis Rheumatol. 69, 2209–2221 (2017)
    • (2017) Arthritis Rheumatol. , vol.69 , pp. 2209-2221
    • Avouac, J.1
  • 49
    • 85039728109 scopus 로고    scopus 로고
    • Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
    • PID: 29263173
    • Hemnes, A. R. & Humbert, M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur. Respir. Rev. 26, 170093 (2017)
    • (2017) Eur. Respir. Rev. , vol.26 , pp. 170093
    • Hemnes, A.R.1    Humbert, M.2
  • 50
    • 84863280800 scopus 로고    scopus 로고
    • BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines
    • PID: 22227206
    • Davies, R. J. et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L604–615 (2012)
    • (2012) Am. J. Physiol. Lung Cell. Mol. Physiol. , vol.302 , pp. L604-L615
    • Davies, R.J.1
  • 51
    • 84924758403 scopus 로고    scopus 로고
    • Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis
    • PID: 25606692
    • Gilbane, A. J. et al. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am. J. Respir. Crit. Care Med. 191, 665–677 (2015)
    • (2015) Am. J. Respir. Crit. Care Med. , vol.191 , pp. 665-677
    • Gilbane, A.J.1
  • 52
    • 84898775777 scopus 로고    scopus 로고
    • Prediction of pulmonary complications and long-term survival in systemic sclerosis
    • PID: 24591477
    • Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 1625–1635 (2014)
    • (2014) Arthritis Rheumatol. , vol.66 , pp. 1625-1635
    • Nihtyanova, S.I.1
  • 53
    • 84999780365 scopus 로고    scopus 로고
    • Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil
    • PID: 27499522
    • Cheong, F. Y., Gower, A. C. & Farber, H. W. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin. Arthritis Rheum. 46, 465–472 (2017)
    • (2017) Semin. Arthritis Rheum. , vol.46 , pp. 465-472
    • Cheong, F.Y.1    Gower, A.C.2    Farber, H.W.3
  • 54
    • 84931431692 scopus 로고    scopus 로고
    • Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension
    • PID: 25956031
    • Good, R. B. et al. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am. J. Pathol. 185, 1850–1858 (2015)
    • (2015) Am. J. Pathol. , vol.185 , pp. 1850-1858
    • Good, R.B.1
  • 55
    • 85031020168 scopus 로고    scopus 로고
    • Brief report: association of elevated adipsin levels with pulmonary arterial hypertension in systemic sclerosis
    • PID: 28651038
    • Korman, B. D. et al. Brief report: association of elevated adipsin levels with pulmonary arterial hypertension in systemic sclerosis. Arthritis Rheumatol. 69, 2062–2068 (2017)
    • (2017) Arthritis Rheumatol. , vol.69 , pp. 2062-2068
    • Korman, B.D.1
  • 56
    • 85030311387 scopus 로고    scopus 로고
    • An MIF Promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis
    • PID: 28668810
    • Bossini-Castillo, L. et al. An MIF Promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis. J. Rheumatol. 44, 1453–1457 (2017)
    • (2017) J. Rheumatol. , vol.44 , pp. 1453-1457
    • Bossini-Castillo, L.1
  • 58
    • 85013817310 scopus 로고    scopus 로고
    • Optical coherence tomography evaluation of pulmonary arterial vasculopathy in systemic sSclerosis
    • PID: 28233825
    • Schwaiger, J. P. et al. Optical coherence tomography evaluation of pulmonary arterial vasculopathy in systemic sclerosis. Sci. Rep. 7, 43304 (2017)
    • (2017) Sci. Rep. , vol.7
    • Schwaiger, J.P.1
  • 59
    • 84891850978 scopus 로고    scopus 로고
    • Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)
    • PID: 24081973
    • Olsson, K. M. 1 & Delcroix, M. et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 129, 57–65 (2014)
    • (2014) Circulation. , vol.129 , pp. 57-65
    • Olsson, K.M.1    Delcroix, M.2
  • 60
    • 84946142144 scopus 로고    scopus 로고
    • Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature
    • PID: 26402988
    • Daraban, A. M. et al. Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature. Rom. J. Intern. Med. 53, 175–183 (2015)
    • (2015) Rom. J. Intern. Med. , vol.53 , pp. 175-183
    • Daraban, A.M.1
  • 61
    • 85038129388 scopus 로고    scopus 로고
    • Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension
    • PID: 29029203
    • Connolly, M. J. et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology 56, 2197–2203 (2017)
    • (2017) Rheumatology , vol.56 , pp. 2197-2203
    • Connolly, M.J.1
  • 62
    • 77950261786 scopus 로고    scopus 로고
    • Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study
    • PID: 19966313
    • Nihtyanova, S. I. et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103, 109–115 (2010)
    • (2010) QJM , vol.103 , pp. 109-115
    • Nihtyanova, S.I.1
  • 63
    • 84991080735 scopus 로고    scopus 로고
    • BSR and BHPR guideline for the treatment of systemic sclerosis
    • PID: 27284161
    • Denton, C. P. et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55, 1906–1910 (2016)
    • (2016) Rheumatology , vol.55 , pp. 1906-1910
    • Denton, C.P.1
  • 64
    • 85019992051 scopus 로고    scopus 로고
    • Severity and features of frailty in systemic sclerosis-associated interstitial lung disease
    • PID: 28732817
    • Guler, S. A. et al. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respir. Med. 129, 1–7 (2017)
    • (2017) Respir. Med. , vol.129 , pp. 1-7
    • Guler, S.A.1
  • 65
    • 84942249727 scopus 로고    scopus 로고
    • Quality of life and functional disability in patients with interstitial lung disease related to systemic sclerosis
    • PID: 26422428
    • Lumetti, F. et al. Quality of life and functional disability in patients with interstitial lung disease related to systemic sclerosis. Acta Biomed. 86, 142–148 (2015)
    • (2015) Acta Biomed. , vol.86 , pp. 142-148
    • Lumetti, F.1
  • 66
    • 84902993757 scopus 로고    scopus 로고
    • Cardiac arrhythmias and conduction defects in systemic sclerosis
    • PID: 24241036
    • Vacca, A. et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology 53, 1172–1177 (2014)
    • (2014) Rheumatology , vol.53 , pp. 1172-1177
    • Vacca, A.1
  • 67
    • 84927130749 scopus 로고    scopus 로고
    • Interstitial lung disease in connective tissue disease—mechanisms and management
    • PID: 25266451
    • Wells, A. U. & Denton, C. P. Interstitial lung disease in connective tissue disease—mechanisms and management. Nat. Rev. Rheumatol. 10, 728–739 (2014)
    • (2014) Nat. Rev. Rheumatol. , vol.10 , pp. 728-739
    • Wells, A.U.1    Denton, C.P.2
  • 68
    • 3242813602 scopus 로고    scopus 로고
    • CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia
    • PID: 15286324
    • Desai, S. R. et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232, 560–567 (2004)
    • (2004) Radiology , vol.232 , pp. 560-567
    • Desai, S.R.1
  • 69
    • 84948406336 scopus 로고    scopus 로고
    • Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease
    • PID: 26316389
    • Suliman, Y. A. et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 67, 3256–3261 (2015)
    • (2015) Arthritis Rheumatol. , vol.67 , pp. 3256-3261
    • Suliman, Y.A.1
  • 70
    • 33846892076 scopus 로고    scopus 로고
    • Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
    • PID: 16868020
    • Buch, M. H. et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann. Rheum. Dis. 66, 169–173 (2007)
    • (2007) Ann. Rheum. Dis. , vol.66 , pp. 169-173
    • Buch, M.H.1
  • 71
    • 84888793944 scopus 로고    scopus 로고
    • Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension
    • Khanna, D. et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum. 65, 3194–3201 (2015)
    • (2015) Arthritis Rheum. , vol.65 , pp. 3194-3201
    • Khanna, D.1
  • 72
    • 85020014395 scopus 로고    scopus 로고
    • Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
    • PID: 28576149
    • Morrisroe, K. et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res. Ther. 19, 122 (2017)
    • (2017) Arthritis Res. Ther. , vol.19 , pp. 122
    • Morrisroe, K.1
  • 73
    • 66449099999 scopus 로고    scopus 로고
    • The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
    • PID: 19479881
    • Hachulla, E. et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 60, 1831–1839 (2009)
    • (2009) Arthritis Rheum. , vol.60 , pp. 1831-1839
    • Hachulla, E.1
  • 74
    • 84887763035 scopus 로고    scopus 로고
    • The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study
    • PID: 24246100
    • Thakkar, V. et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res. Ther. 15, R193 (2013)
    • (2013) Arthritis Res. Ther. , vol.15 , pp. R193
    • Thakkar, V.1
  • 75
    • 84924325369 scopus 로고    scopus 로고
    • A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
    • PID: 25596924
    • Hao, Y. et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res. Ther. 17, 7 (2015)
    • (2015) Arthritis Res. Ther. , vol.17 , pp. 7
    • Hao, Y.1
  • 76
    • 84888788607 scopus 로고    scopus 로고
    • Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations
    • PID: 24293467
    • Schwaiger, J. P., Khanna, D. & Gerry Coghlan, J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur. Respir. Rev. 22, 515–525 (2013)
    • (2013) Eur. Respir. Rev. , vol.22 , pp. 515-525
    • Schwaiger, J.P.1    Khanna, D.2    Gerry Coghlan, J.3
  • 77
    • 84902249499 scopus 로고    scopus 로고
    • Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
    • PID: 23687283
    • Coghlan, J. G. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann. Rheum. Dis. 73, 1340–1349 (2014)
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 1340-1349
    • Coghlan, J.G.1
  • 78
    • 84962053233 scopus 로고    scopus 로고
    • Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension
    • PID: 26636545
    • Antoniou, K. M. et al. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol. 68, 1004–1012 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 1004-1012
    • Antoniou, K.M.1
  • 79
    • 80155206329 scopus 로고    scopus 로고
    • Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests
    • PID: 21769839
    • Schreiber, B. E. et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum. 63, 3531–3539 (2011)
    • (2011) Arthritis Rheum. , vol.63 , pp. 3531-3539
    • Schreiber, B.E.1
  • 80
    • 85038238925 scopus 로고    scopus 로고
    • Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort
    • PID: 29061853
    • Mihai, C. et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann. Rheum. Dis. 77, 128–132 (2018)
    • (2018) Ann. Rheum. Dis. , vol.77 , pp. 128-132
    • Mihai, C.1
  • 81
    • 84956714806 scopus 로고    scopus 로고
    • Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension
    • PID: 26415038
    • Sobanski, V. et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 68, 484–493 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 484-493
    • Sobanski, V.1
  • 82
    • 84875728533 scopus 로고    scopus 로고
    • Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension
    • PID: 23280155
    • Valerio, C. J., Schreiber, B. E., Handler, C. E., Denton, C. P. & Coghlan, J. G. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 65, 1074–1084 (2013)
    • (2013) Arthritis Rheum. , vol.65 , pp. 1074-1084
    • Valerio, C.J.1    Schreiber, B.E.2    Handler, C.E.3    Denton, C.P.4    Coghlan, J.G.5
  • 83
    • 84927780552 scopus 로고    scopus 로고
    • Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study
    • PID: 25491468
    • Visovatti, S. H. et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res. Ther. 16, 493 (2014)
    • (2014) Arthritis Res. Ther. , vol.16 , pp. 493
    • Visovatti, S.H.1
  • 84
    • 84863812040 scopus 로고    scopus 로고
    • Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry
    • PID: 22307943
    • Bae, S. et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann. Rheum. Dis. 71, 1335–1342 (2012)
    • (2012) Ann. Rheum. Dis. , vol.71 , pp. 1335-1342
    • Bae, S.1
  • 85
    • 85018928505 scopus 로고    scopus 로고
    • Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: observations from the PHAROS cohort
    • PID: 28500695
    • Lammi, M. R. et al. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: observations from the PHAROS cohort. Respirology 22, 1386–1392 (2017)
    • (2017) Respirology , vol.22 , pp. 1386-1392
    • Lammi, M.R.1
  • 86
    • 84990884932 scopus 로고    scopus 로고
    • Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum
    • PID: 27443433
    • Opitz, C. F. et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J. Am. Coll. Cardiol. 68, 368–378 (2016)
    • (2016) J. Am. Coll. Cardiol. , vol.68 , pp. 368-378
    • Opitz, C.F.1
  • 87
    • 84987678141 scopus 로고    scopus 로고
    • Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry
    • PID: 24992469
    • Chung, L. et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146, 1494–1504 (2014)
    • (2014) Chest , vol.146 , pp. 1494-1504
    • Chung, L.1
  • 88
    • 84943272997 scopus 로고    scopus 로고
    • 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)
    • PID: 26318161
    • Galiè, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46, 903–975 (2015)
    • (2015) Eur. Respir. J. , vol.46 , pp. 903-975
    • Galiè, N.1
  • 89
    • 84880146612 scopus 로고    scopus 로고
    • Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients
    • PID: 22789029
    • Hager, W. D. et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin. Respir. J. 7, 227–236 (2013)
    • (2013) Clin. Respir. J. , vol.7 , pp. 227-236
    • Hager, W.D.1
  • 90
    • 77956461669 scopus 로고    scopus 로고
    • Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis
    • PID: 20551099
    • Walkey, A. J., Ieong, M., Alikhan, M. & Farber, H. W. Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. J. Rheumatol. 37, 1871–1877 (2010)
    • (2010) J. Rheumatol. , vol.37 , pp. 1871-1877
    • Walkey, A.J.1    Ieong, M.2    Alikhan, M.3    Farber, H.W.4
  • 91
    • 85022044840 scopus 로고    scopus 로고
    • Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes
    • PID: 28223154
    • Ramjug, S. et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest 152, 92–102 (2017)
    • (2017) Chest , vol.152 , pp. 92-102
    • Ramjug, S.1
  • 92
    • 35948985145 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody
    • PID: 17937469
    • Steen, V. D., Lucas, M., Fertig, N. & Medsger, T. A. Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J. Rheumatol. 34, 2230–2235 (2007)
    • (2007) J. Rheumatol. , vol.34 , pp. 2230-2235
    • Steen, V.D.1    Lucas, M.2    Fertig, N.3    Medsger, T.A.4
  • 93
    • 84955693022 scopus 로고    scopus 로고
    • Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry
    • PID: 26210782
    • Hinchcliff, M. et al. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry. Semin. Arthritis Rheum. 45, 309–314 (2015)
    • (2015) Semin. Arthritis Rheum. , vol.45 , pp. 309-314
    • Hinchcliff, M.1
  • 94
    • 85007442988 scopus 로고    scopus 로고
    • Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity
    • PID: 28028682
    • Michelfelder, M. et al. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin. Rheumatol. 36, 381–390 (2017)
    • (2017) Clin. Rheumatol. , vol.36 , pp. 381-390
    • Michelfelder, M.1
  • 95
    • 0037098050 scopus 로고    scopus 로고
    • Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
    • PID: 12070056
    • Bouros, D. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165, 1581–1586 (2002)
    • (2002) Am. J. Respir. Crit. Care Med. , vol.165 , pp. 1581-1586
    • Bouros, D.1
  • 96
    • 0028360565 scopus 로고
    • Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
    • PID: 8004317
    • Wells, A. U. et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 149, 1583–1590 (1994)
    • (1994) Am. J. Respir. Crit. Care Med. , vol.149 , pp. 1583-1590
    • Wells, A.U.1
  • 97
    • 85021648682 scopus 로고    scopus 로고
    • Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease
    • PID: 28666014
    • Enomoto, Y. et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLOS One. 12, e0180283 (2017)
    • (2017) PLOS One. , vol.12
    • Enomoto, Y.1
  • 98
    • 85047090949 scopus 로고    scopus 로고
    • Radiological pleuroparenchymal fibroelastosis associated to limited cutaneous systemic sclerosis: a case report
    • PID: 29776440
    • Hassoun, D. et al. Radiological pleuroparenchymal fibroelastosis associated to limited cutaneous systemic sclerosis: a case report. BMC Pulm. Med. 18, 73 (2018)
    • (2018) BMC Pulm. Med. , vol.18 , pp. 73
    • Hassoun, D.1
  • 99
    • 80155159965 scopus 로고    scopus 로고
    • Clinical and serological hallmarks of systemic sclerosis overlap syndromes
    • PID: 21844148
    • Pakozdi, A. et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J. Rheumatol. 38, 2406–2409 (2011)
    • (2011) J. Rheumatol. , vol.38 , pp. 2406-2409
    • Pakozdi, A.1
  • 100
    • 85016995712 scopus 로고    scopus 로고
    • Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time
    • PID: 28604345
    • Nihtyanova, S. I. & Denton, C. P. Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time. J. Rheumatol. 44, 404–406 (2017)
    • (2017) J. Rheumatol. , vol.44 , pp. 404-406
    • Nihtyanova, S.I.1    Denton, C.P.2
  • 101
    • 70350787026 scopus 로고    scopus 로고
    • A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis
    • PID: 19696067
    • Nihtyanova, S. I., Parker, J. C., Black, C. M., Bunn, C. C. & Denton, C. P. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology 48, 1218–1221 (2009)
    • (2009) Rheumatology , vol.48 , pp. 1218-1221
    • Nihtyanova, S.I.1    Parker, J.C.2    Black, C.M.3    Bunn, C.C.4    Denton, C.P.5
  • 102
    • 44449152061 scopus 로고    scopus 로고
    • Interstitial lung disease in systemic sclerosis: a simple staging system
    • PID: 18369202
    • Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248–1254 (2008)
    • (2008) Am. J. Respir. Crit. Care Med. , vol.177 , pp. 1248-1254
    • Goh, N.S.1
  • 103
    • 84939481098 scopus 로고    scopus 로고
    • Reliability, validity and responsiveness to change of the Saint George’s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis
    • PID: 25667436
    • Wallace, B. et al. Reliability, validity and responsiveness to change of the Saint George’s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology 54, 1369–1379 (2015)
    • (2015) Rheumatology , vol.54 , pp. 1369-1379
    • Wallace, B.1
  • 104
    • 84871132776 scopus 로고    scopus 로고
    • Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
    • PID: 23065360
    • Moore, O. A. et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 52, 155–160 (2013)
    • (2013) Rheumatology , vol.52 , pp. 155-160
    • Moore, O.A.1
  • 105
    • 84954348461 scopus 로고    scopus 로고
    • Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis
    • PID: 25452309
    • Tashkin, D. P. et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann. Rheum. Dis. 75, 374–381 (2016)
    • (2016) Ann. Rheum. Dis. , vol.75 , pp. 374-381
    • Tashkin, D.P.1
  • 106
    • 85007484082 scopus 로고    scopus 로고
    • Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
    • PID: 28038680
    • Volkmann, E. R. et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res. Ther. 18, 305 (2016)
    • (2016) Arthritis Res. Ther. , vol.18 , pp. 305
    • Volkmann, E.R.1
  • 107
    • 85048222865 scopus 로고    scopus 로고
    • Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
    • Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum. Dis. 10.1136/annrheumdis-2018-213201 (2018)
    • (2018) Ann Rheum. Dis.
    • Wu, W.1
  • 108
    • 84938152992 scopus 로고    scopus 로고
    • Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis
    • PID: 25916462
    • Hoffmann-Vold, A. M. et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 67, 2205–2212 (2015)
    • (2015) Arthritis Rheumatol. , vol.67 , pp. 2205-2212
    • Hoffmann-Vold, A.M.1
  • 109
    • 84951847053 scopus 로고    scopus 로고
    • Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials
    • PID: 26704522
    • Khanna, D. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res. Ther. 17, 372 (2015)
    • (2015) Arthritis Res. Ther. , vol.17 , pp. 372
    • Khanna, D.1
  • 110
    • 84961832110 scopus 로고    scopus 로고
    • Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability
    • PID: 26930658
    • Salaffi, F. et al. Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability. PLOS One 11, e0149240 (2016)
    • (2016) PLOS One , vol.11
    • Salaffi, F.1
  • 111
    • 84902844800 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial
    • PID: 25058083
    • van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014)
    • (2014) JAMA , vol.311 , pp. 2490-2498
    • van Laar, J.M.1
  • 112
    • 85024859154 scopus 로고    scopus 로고
    • Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis
    • PID: 28426895
    • Goh, N. S. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 69, 1670–1678 (2017)
    • (2017) Arthritis Rheumatol. , vol.69 , pp. 1670-1678
    • Goh, N.S.1
  • 113
    • 84956807922 scopus 로고    scopus 로고
    • The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis
    • PID: 26808827
    • Khanna, D. et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 68, 299–311 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 299-311
    • Khanna, D.1
  • 114
    • 84946209246 scopus 로고    scopus 로고
    • Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease
    • PID: 26243401
    • Moore, O. A. et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin. Exp. Rheumatol. 33 (Suppl. 91), S111–S116 (2015)
    • (2015) Clin. Exp. Rheumatol. , vol.33 , pp. S111-S116
    • Moore, O.A.1
  • 115
    • 85052223053 scopus 로고    scopus 로고
    • Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype
    • Chung, L. et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 38, 1383–1394 (2011)
    • (2011) Chest , vol.38 , pp. 1383-1394
    • Chung, L.1
  • 116
    • 85006282765 scopus 로고    scopus 로고
    • Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters
    • Fischer, A. et al. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin. Exp. Rheumatol. 32 (Suppl. 91), S109–S114 (2014)
    • (2014) Clin. Exp. Rheumatol. , vol.32 , pp. S109-S114
    • Fischer, A.1
  • 117
    • 85039984521 scopus 로고    scopus 로고
    • Cyclophosphamide for connective tissue disease-associated interstitial lung disease
    • PID: 29297205
    • Barnes, H., Holland, A. E., Westall, G. P., Goh, N. S. & Glaspole, I. N. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev. 1, CD010908 (2018)
    • (2018) Cochrane Database Syst. Rev. , vol.1 , pp. CD010908
    • Barnes, H.1    Holland, A.E.2    Westall, G.P.3    Goh, N.S.4    Glaspole, I.N.5
  • 118
    • 33745227399 scopus 로고    scopus 로고
    • Cyclophosphamide versus placebo in scleroderma lung disease
    • PID: 16790698
    • Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J.Med. 354, 2655–2666 (2006)
    • (2006) N. Engl. J.Med. , vol.354 , pp. 2655-2666
    • Tashkin, D.P.1
  • 119
    • 36249001195 scopus 로고    scopus 로고
    • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    • PID: 17717203
    • Tashkin, D. P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176, 1026–1034 (2007)
    • (2007) Am. J. Respir. Crit. Care Med. , vol.176 , pp. 1026-1034
    • Tashkin, D.P.1
  • 120
    • 33845643063 scopus 로고    scopus 로고
    • A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
    • PID: 17133610
    • Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006)
    • (2006) Arthritis Rheum. , vol.54 , pp. 3962-3970
    • Hoyles, R.K.1
  • 121
    • 85017100759 scopus 로고    scopus 로고
    • Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II
    • PID: 28012804
    • Tashkin, D. P. et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II. Chest 151, 813–820 (2017)
    • (2017) Chest , vol.151 , pp. 813-820
    • Tashkin, D.P.1
  • 122
    • 85021382806 scopus 로고    scopus 로고
    • Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II
    • PID: 28376288
    • Volkmann, E. R. et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 69, 1451–1460 (2017)
    • (2017) Arthritis Rheumatol. , vol.69 , pp. 1451-1460
    • Volkmann, E.R.1
  • 123
    • 84989835495 scopus 로고    scopus 로고
    • Scleroderma Lung Study II — clarity or obfuscation? Lancet
    • Denton, C. P. Scleroderma Lung Study II — clarity or obfuscation? Lancet Respir. Med. 4, 678–679 (2016)
    • (2016) Respir. Med. , vol.4 , pp. 678-679
    • Denton, C.P.1
  • 124
    • 80051468836 scopus 로고    scopus 로고
    • Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
    • PID: 21777972
    • Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498–506 (2011)
    • (2011) Lancet , vol.378 , pp. 498-506
    • Burt, R.K.1
  • 125
    • 85040338916 scopus 로고    scopus 로고
    • Myeloablative autologous stem-cell transplantation for severe scleroderma
    • PID: 29298160
    • Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018)
    • (2018) N. Engl. J. Med. , vol.378 , pp. 35-47
    • Sullivan, K.M.1
  • 126
    • 85027580376 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
    • PID: 28619061
    • Saunders, P. et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 18, 275 (2017)
    • (2017) Trials , vol.18
    • Saunders, P.1
  • 127
    • 85048167375 scopus 로고    scopus 로고
    • Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
    • Denton, C. P. et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann. Rheum. Dis. 10.1136/annrheumdis-2018-213031 (2018)
    • (2018) Ann. Rheum. Dis.
    • Denton, C.P.1
  • 128
    • 84978920193 scopus 로고    scopus 로고
    • Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
    • PID: 27156934
    • Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630–2640 (2016)
    • (2016) Lancet , vol.387 , pp. 2630-2640
    • Khanna, D.1
  • 129
    • 84992536249 scopus 로고    scopus 로고
    • Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis
    • PID: 27273608
    • Betteridge, Z. E. et al. Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthritis Rheumatol. 68, 2778–2783 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 2778-2783
    • Betteridge, Z.E.1
  • 130
    • 85041598565 scopus 로고    scopus 로고
    • Defective regulation of autoreactive IL-6-producing transitional B lymphocytes is associated with disease in patients with systemic sclerosis
    • PID: 29193892
    • Taher, T. E. et al. Defective regulation of autoreactive IL-6-producing transitional B lymphocytes is associated with disease in patients with systemic sclerosis. Arthritis Rheumatol. 70, 450–461 (2018)
    • (2018) Arthritis Rheumatol. , vol.70 , pp. 450-461
    • Taher, T.E.1
  • 131
    • 84865814629 scopus 로고    scopus 로고
    • Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
    • PID: 22282550
    • Keir, G. J. et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur. Respir. J. 40, 641–648 (2012)
    • (2012) Eur. Respir. J. , vol.40 , pp. 641-648
    • Keir, G.J.1
  • 132
    • 84936791793 scopus 로고    scopus 로고
    • Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
    • PID: 26098215
    • Rice, L. M. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 125, 2795–2807 (2015)
    • (2015) J. Clin. Invest. , vol.125 , pp. 2795-2807
    • Rice, L.M.1
  • 133
    • 85052220443 scopus 로고    scopus 로고
    • ClinicalTrials.gov
    • US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02745145 (2018)
    • (2018)
  • 134
    • 85045907844 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02921971 (2018)
    • (2018) Clinicaltrials.Gov
  • 135
    • 84984998138 scopus 로고    scopus 로고
    • An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial
    • PID: 27370878
    • Khanna, D. et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J. Rheumatol. 43, 1672–1679 (2016)
    • (2016) J. Rheumatol. , vol.43 , pp. 1672-1679
    • Khanna, D.1
  • 136
    • 85045907844 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03221257 (2018)
    • (2018) Clinicaltrials.Gov
  • 137
    • 85031689905 scopus 로고    scopus 로고
    • Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)
    • PID: 28664834
    • Distler, O. et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin. Exp. Rheumatol. 35 (Suppl. 106), 75–81 (2017)
    • (2017) Clin. Exp. Rheumatol. , vol.35 , pp. 75-81
    • Distler, O.1
  • 138
    • 85045907844 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02597933 (2018)
    • (2018) Clinicaltrials.Gov
  • 139
    • 85042691379 scopus 로고    scopus 로고
    • Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase ii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • PID: 29093152
    • Hsu, V. M. et al. Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase ii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J. Rheumatol. 45, 405–410 (2017)
    • (2017) J. Rheumatol. , vol.45 , pp. 405-410
    • Hsu, V.M.1
  • 140
    • 0032588623 scopus 로고    scopus 로고
    • Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial
    • PID: 10025924
    • Black, C. M. et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42, 299–305 (1999)
    • (1999) Arthritis Rheum. , vol.42 , pp. 299-305
    • Black, C.M.1
  • 141
    • 77954222367 scopus 로고    scopus 로고
    • Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis
    • PID: 20506355
    • Seibold, J. R. et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 62, 2101–2108 (2010)
    • (2010) Arthritis Rheum. , vol.62 , pp. 2101-2108
    • Seibold, J.R.1
  • 142
    • 85052220883 scopus 로고    scopus 로고
    • Managing systemic sclerosis-related interstitial lung disease in the modern treatment era
    • Volkmann, E. R., Chung, A. & Tashkin, D. P. Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J. Scleroderma Relat. Disord. 2, 72–83 (2017)
    • (2017) J. Scleroderma Relat. Disord. , vol.2 , pp. 72-83
    • Volkmann, E.R.1    Chung, A.2    Tashkin, D.P.3
  • 143
    • 85019365988 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development
    • PID: 28524624
    • Ghataorhe, P. et al. Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development. J. Intern. Med. 282, 129–141 (2017)
    • (2017) J. Intern. Med. , vol.282 , pp. 129-141
    • Ghataorhe, P.1
  • 144
    • 17144452827 scopus 로고    scopus 로고
    • Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
    • PID: 10733441
    • Badesch, D. B. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425–434 (2000)
    • (2000) Ann. Intern. Med. , vol.132 , pp. 425-434
    • Badesch, D.B.1
  • 145
    • 70450162190 scopus 로고    scopus 로고
    • Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    • PID: 19723905
    • Badesch, D. B. et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J. Rheumatol 36, 2244–2249 (2009)
    • (2009) J. Rheumatol , vol.36 , pp. 2244-2249
    • Badesch, D.B.1
  • 146
    • 84978087054 scopus 로고    scopus 로고
    • Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a subgroup analysis of the ARIES-E clinical trial
    • PID: 27492539
    • Fischer, A. et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a subgroup analysis of the ARIES-E clinical trial. Respir. Med. 117, 254–263 (2016)
    • (2016) Respir. Med. , vol.117 , pp. 254-263
    • Fischer, A.1
  • 147
    • 78649361810 scopus 로고    scopus 로고
    • Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension
    • PID: 20675359
    • Valerio, C. J. et al. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology 49, 2147–2153 (2010)
    • (2010) Rheumatology , vol.49 , pp. 2147-2153
    • Valerio, C.J.1
  • 148
    • 36849073290 scopus 로고    scopus 로고
    • Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    • PID: 17985403
    • Badesch, D. B. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 34, 2417–2422 (2007)
    • (2007) J. Rheumatol. , vol.34 , pp. 2417-2422
    • Badesch, D.B.1
  • 149
    • 33750344748 scopus 로고    scopus 로고
    • Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
    • PID: 16793845
    • Denton, C. P., Humbert, M., Rubin, L. & Black, C. M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65, 1336–1340 (2006)
    • (2006) Ann. Rheum. Dis. , vol.65 , pp. 1336-1340
    • Denton, C.P.1    Humbert, M.2    Rubin, L.3    Black, C.M.4
  • 150
    • 84883108940 scopus 로고    scopus 로고
    • Macitentan and morbidity and mortality in pulmonary arterial hypertension
    • PID: 23984728
    • Pulido, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809–818 (2013)
    • (2013) N. Engl. J. Med. , vol.369 , pp. 809-818
    • Pulido, T.1
  • 151
    • 84951967550 scopus 로고    scopus 로고
    • Selexipag for the treatment of pulmonary arterial hypertension
    • PID: 26699168
    • Sitbon, O. et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 373, 2522–2533 (2015)
    • (2015) N. Engl. J. Med. , vol.373 , pp. 2522-2533
    • Sitbon, O.1
  • 152
    • 84938823530 scopus 로고    scopus 로고
    • Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
    • PID: 26308684
    • Galiè, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834–844 (2015)
    • (2015) N. Engl. J. Med. , vol.373 , pp. 834-844
    • Galiè, N.1
  • 153
    • 84946565060 scopus 로고    scopus 로고
    • Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension
    • PID: 26360334
    • Hassoun, P. M. et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 192, 1102–1110 (2015)
    • (2015) Am. J. Respir. Crit. Care Med. , vol.192 , pp. 1102-1110
    • Hassoun, P.M.1
  • 154
    • 85010425197 scopus 로고    scopus 로고
    • Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
    • PID: 28039187
    • Coghlan, J. G. et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann. Rheum. Dis. 76, 1219–1227 (2017)
    • (2017) Ann. Rheum. Dis. , vol.76 , pp. 1219-1227
    • Coghlan, J.G.1
  • 155
    • 85027881389 scopus 로고    scopus 로고
    • Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
    • PID: 28818881
    • Gaine, S. et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur. Respir. J. 50, 1602493 (2017)
    • (2017) Eur. Respir. J. , vol.50 , pp. 1602493
    • Gaine, S.1
  • 156
    • 84979497388 scopus 로고    scopus 로고
    • Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
    • PID: 27457511
    • Humbert, M. et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann. Rheum. Dis. 76, 422–426 (2017)
    • (2017) Ann. Rheum. Dis. , vol.76 , pp. 422-426
    • Humbert, M.1
  • 157
    • 84901855893 scopus 로고    scopus 로고
    • Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
    • PID: 24627535
    • Sitbon, O. et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur. Respir. J. 43, 1691–1697 (2014)
    • (2014) Eur. Respir. J. , vol.43 , pp. 1691-1697
    • Sitbon, O.1
  • 158
    • 84908548314 scopus 로고    scopus 로고
    • Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group
    • PID: 25027464
    • Launay, D. et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Med. 43, e345–363 (2014)
    • (2014) Presse Med. , vol.43 , pp. e345-e363
    • Launay, D.1
  • 159
    • 84989339218 scopus 로고    scopus 로고
    • Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience
    • PID: 27078625
    • Miele, C. H. et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann. Am. Thorac Soc. 13, 793–802 (2016)
    • (2016) Ann. Am. Thorac Soc. , vol.13 , pp. 793-802
    • Miele, C.H.1
  • 160
    • 84928637159 scopus 로고    scopus 로고
    • Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study
    • PID: 25581250
    • Bernstein, E. J. et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 67, 1314–1322 (2015)
    • (2015) Arthritis Rheumatol. , vol.67 , pp. 1314-1322
    • Bernstein, E.J.1
  • 161
    • 77957848190 scopus 로고    scopus 로고
    • Systemic sclerosis and bilateral lung transplantation: a single centre experience
    • PID: 20351032
    • Saggar, R. et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur. Respir. J. 36, 893–900 (2010)
    • (2010) Eur. Respir. J. , vol.36 , pp. 893-900
    • Saggar, R.1
  • 162
    • 84890312604 scopus 로고    scopus 로고
    • Survival after lung transplantation in systemic sclerosis. A systematic review
    • PID: 24113572
    • Khan, I. Y. et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir. Med. 107, 2081–2087 (2013)
    • (2013) Respir. Med. , vol.107 , pp. 2081-2087
    • Khan, I.Y.1
  • 163
    • 85020703821 scopus 로고    scopus 로고
    • Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
    • PID: 28188239
    • Herrick, A. L. et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann. Rheum. Dis. 76, 1207–1218 (2017)
    • (2017) Ann. Rheum. Dis. , vol.76 , pp. 1207-1218
    • Herrick, A.L.1
  • 164
    • 84962073214 scopus 로고    scopus 로고
    • Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis
    • PID: 26554637
    • Domsic, R. T. et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 68, 993–1003 (2016)
    • (2016) Arthritis Rheumatol. , vol.68 , pp. 993-1003
    • Domsic, R.T.1
  • 165
    • 84901599531 scopus 로고    scopus 로고
    • Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis
    • PID: 24470430
    • Domsic, R. T. et al. Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 66, 1616–1624 (2014)
    • (2014) Arthritis Rheumatol. , vol.66 , pp. 1616-1624
    • Domsic, R.T.1
  • 166
    • 84995487524 scopus 로고    scopus 로고
    • Update of EULAR recommendations for the treatment of systemic sclerosis
    • PID: 27941129
    • Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327–1339 (2017)
    • (2017) Ann. Rheum. Dis. , vol.76 , pp. 1327-1339
    • Kowal-Bielecka, O.1
  • 167
    • 84905255169 scopus 로고    scopus 로고
    • Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study
    • PID: 24709277
    • Hsu, V. M. et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin. Arthritis Rheum. 44, 55–62 (2014)
    • (2014) Semin. Arthritis Rheum. , vol.44 , pp. 55-62
    • Hsu, V.M.1
  • 168
    • 0036682273 scopus 로고    scopus 로고
    • Inhaled iloprost for severe pulmonary hypertension
    • PID: 12151469
    • Olschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322–329 (2002)
    • (2002) N. Engl. J. Med. , vol.347 , pp. 322-329
    • Olschewski, H.1
  • 169
    • 4143121167 scopus 로고    scopus 로고
    • Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease
    • PID: 15302727
    • Oudiz, R. J. et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126, 420–427 (2004)
    • (2004) Chest , vol.126 , pp. 420-427
    • Oudiz, R.J.1
  • 170
    • 33646255654 scopus 로고    scopus 로고
    • Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    • PID: 16697324
    • Barst, R. J. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47, 2049–2056 (2006)
    • (2006) J. Am. Coll. Cardiol. , vol.47 , pp. 2049-2056
    • Barst, R.J.1
  • 171
    • 84938903925 scopus 로고    scopus 로고
    • Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
    • PID: 26113687
    • McLaughlin, V. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur. Respir. J. 46, 405–413 (2015)
    • (2015) Eur. Respir. J. , vol.46 , pp. 405-413
    • McLaughlin, V.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.